WEREWOLF THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 521.78 thousand shares for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2024-08-08
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2024-06-30 was 521.78K shares.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2023-06-30 was 0.00 shares.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2021-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2020-06-30 was 9.26M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 6 month |
|---|---|---|
| 2024-06-30 | 521.78K shares 10-Q · filed 2024-08-08 | 260.89K shares 10-Q · filed 2024-08-08 |
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-08 | 0.00 shares 10-Q · filed 2024-08-08 |
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-08-12 | 0.00 shares 10-Q · filed 2021-08-12 |
| 2020-06-30 | 9.26M shares 10-Q · filed 2021-08-12 | 0.00 shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |